MINIMUM bio
The undruggable proteome has no place to hide
At a glance
-
Development stage
Prototype developed
-
Investment stage
Seed
-
UNSW affiliation
UNSW co-locator
-
Technology readiness level
TRL 3
-
Female led
Yes
MINIMUM bio is accelerating molecular glue discovery with scalable compound generation and proteome-wide screening.
-
MINIMUM bio's platform has two core components.
- First, a biosynthetic platform reprograms the rapamycin assembly line to generate millions of novel rapamycin-derived compounds (rapalogs)
- Second, Mercurious® screens these compounds against the expressed human proteome using proprietary proteome screening, identifying binding targets in 1–2 weeks.
-
The pharmaceutical industry spends 3–5 years and US$50–100M identifying and validating a single drug target, while molecular glues, the fastest-growing drug modality, are still largely discovered by accident. No platform systematically generates FKBP12-recruiting compounds (a type of molecular glue) at scale and rapidly identifies their targets proteome-wide. This bottleneck costs the industry billions annually.
-
Tier 1 pharmaceutical companies and biotech firms developing oncology, immunology, longevity or molecular glue therapeutics requiring first-in-class FKBP12-recruiting assets and targets.
-
- US$1M pre-Seed SAFE note with top 5 Pharma
- AbbVie & WEHI pilots completed
- Federal AC grant ($1M) completed
- NSW MVP grant ($50K) completed
Discover more UNSW spinouts
Search our catalogue of active spinouts and tech for license.